In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Headline
The AHA Sept. 15 released a preview for Frontiers, a three-episode documentary series from the AHA’s Advancing Health Podcast on rural maternal health.…
Headline
The Rural Maternal Health Data Support program, supported by the Health Resources and Services Administration, has launched a data repository that allows users…
Headline
The National Institutes of Health has launched its Connecting the Community for Maternal Health Challenge: Research Capacity Building in Maternity Care Deserts…
Headline
A report on obstetric services in hospitals by the University of Minnesota Rural Health Research Center found that between 2010 and 2024, 718 hospitals…
Headline
In this conversation, Kardie Tobb, D.O., a non-invasive preventative cardiologist at Cone Health, explains how multidisciplinary teams are breaking down…
Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…